ModifiedUnitedHealthcarePolicy CS001NJ.Q

Ablative Treatment for Spinal Pain (for New Jersey Only)

This New Jersey–specific medical policy governs coverage and medical necessity determinations for ablative procedures used to treat spinal pain (facet joints, sacroiliac joint, basivertebral nerve, etc.) for UnitedHealthcare members in New Jersey.

Policy Summary

PayerUnitedHealthcare

PolicyAblative Treatment for Spinal Pain (for New Jersey Only)

Policy CodePolicy CS001NJ.Q

Change TypeClinical evidence and references updatedpolicy version archived

Effective DateMarch 1, 2026

Next Review DateN/A

Key ActionBefore requesting authorization for intraosseous BVN RFA, document ≥6 months of CLBP, Modic type 1 or 2 on MRI at treated levels, prior conservative therapies, and baseline ODI and pain scores.

SourceLink

POLICY UPDATE CHANGES

Updated Clinical Evidence and References sections to reflect the most current information; archived previous policy version CS001NJ.P.

Multiple techniqueslisted as unproven / not medically necessary

NJ-onlystate applicability

249 (78%)BVNA 5‑yr completers

03/01/2026policy revision date

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Unproven / Not Medically Necessary Ablative Procedures

The following ablative procedures and techniques are considered unproven or not medically necessary due to insufficient evidence of safety and/or efficacy, or because evidence is conflicting or of low quality. Coverage is not supported unless specific, guideline-based or high-quality randomized controlled trial evidence demonstrates clinically meaningful benefits for health outcomes.

Pulsed Radiofrequency Ablation (PRFA) of the facet nerves of the cervical, thoracic, or lumbar region, sacral nerve root, or dorsal root ganglion — unproven / not medically necessary.

Endoscopic radiofrequency ablation / endoscopic rhizotomy — unproven / not medically necessary.

Cryoablation (cryodenervation, cryoneurolysis, cryosurgery, or cryoanesthesia) — unproven / not medically necessary.

Cooled Radiofrequency Ablation (CRFA) for facet or sacroiliac joints — insufficient evidence to establish safety and efficacy; investigational / not medically necessary.

Chemical ablation (including but not limited to alcohol, phenol, sodium morrhuate) — insufficient evidence to establish safety and efficacy; investigational / not medically necessary.

Laser ablation (including pulsed, continuous, or low-level) — insufficient evidence to establish safety and efficacy; investigational / not medically necessary.

Ablation to treat sacroiliac joint (SIJ) pain when performed with techniques lacking adequate high-quality evidence — unproven / not medically necessary.

CRFA and Other Ablation Modalities — Evidence Summary and Implications

Evidence summary and implications for Cooled Radiofrequency Ablation (CRFA) and other ablation modalities:

Systematic reviews and technology assessments (AHRQ, Hayes) report low- to moderate-quality evidence for CRFA with heterogeneity across studies and limited duration of follow-up; larger, well-designed RCTs with longer-term outcomes are needed.

Existing RCTs and comparative studies for CRFA show mixed results: some trials suggest short-term improvements in pain and function for SIJ-mediated pain, while others show no clear advantage over conventional RFA; evidence beyond 6–12 months is limited.

Observational studies and case series for various novel ablation techniques (pulsed RFA, endoscopic RFA, cryoablation, chemical and laser ablation) report promising symptom change in some cohorts but are limited by small sample sizes, lack of controls, and inconsistent outcome measurement.

Clinical practice guidelines (ASIPP, ASRA, NICE, NASS) provide conditional or limited recommendations for some RFA techniques (eg, thermal RFA for facet-mediated pain) but emphasize the need for diagnostic blocks, patient selection, and repeat-procedure limits. Guidelines find insufficient evidence to recommend several newer modalities.

Chemical and Laser Ablation — Not Established

Chemical and laser ablation — coverage stance and rationale:

Chemical ablation (eg, intraneural or perineural alcohol or phenol neurolysis) lacks sufficient high-quality evidence from randomized, controlled trials demonstrating long-term benefit and acceptable safety for routine treatment of spinal pain — investigational / not medically necessary.

Laser ablation/neurolysis (pulsed, continuous, or low-level) is supported mainly by case series and small observational studies with short follow-up and is therefore considered investigational / not medically necessary.

Evidence and Guideline-based Criteria

Guideline and evidence-based considerations relevant to coverage decisions:

ASIPP (2020): Moderate strength recommendation for cervical and lumbar thermal RFA (evidence level II); recommends repeat procedures only as medically necessary and suggests intervals of approximately 6 months or longer if ≥50% relief is obtained for 5–6 months.

ASRA/Consensus (2020): Medial branch blocks are recommended as the prognostic screening test before lumbar facet RFA; repeat RFA recommended for recurrence if good initial outcome, and typically no more than two times per year.

NICE (2016, updated 2020) and NASS (2020): Recommend consideration of radiofrequency denervation for carefully selected patients (positive diagnostic medial branch blocks, moderate to severe localized pain) and note insufficient evidence for several newer ablation modalities.

Technology assessments (Hayes; AHRQ reviews) emphasize the need for larger, high-quality RCTs with longer follow-up, standardized techniques, and consistent outcome measures before broad adoption of many novel ablation approaches.

Coverage note: FDA device clearance is informational and not a sole basis for coverage. Distinguish between device regulatory status and clinical evidence for a given procedural indication; devices cleared for use in ablation therapies do not, by themselves, establish that a particular ablation technique improves clinically meaningful outcomes.

Applicable Procedure and Billing Codes

Applicable/Referenced Procedure CodesCPT

22899	Unlisted procedure, spine [when used to report the Intracept procedure or cooled radiofrequency ablation]
27299	Unlisted procedure, pelvis or hip joint
64625	Radiofrequency ablation, nerves innervating the sacroiliac joint, with image guidance (i.e., fluoroscopy or computed tomography)
64628	Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; first 2 vertebral bodies, lumbar or sacral
64629	Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; each additional vertebral body, lumbar or sacral (List separately in addition to code for primary procedure)
64999	Unlisted procedure, nervous system

Responder definition (CRFA vs RFA trial)

Responder threshold (CRFA vs RFA trial)>= 50% reduction in Numeric Rating Scale (NRS) at 6 months

Primary outcome usedProportion of responders defined as >=50% NRS reduction at 6 months in McCormick et al. (2019)

Secondary outcomes referencedNRS, Oswestry Disability Index (ODI), and Patient Global Impression of Change

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Required for BVN RFA

Prior authorization is required for basivertebral nerve (BVN) radiofrequency ablation (RFA). Requests should document refractory chronic low back pain (CLBP) of adequate duration, imaging showing Modic type 1 or 2 endplate changes between L3 and S1, and prior conservative therapies and diagnostic steps (see below). Inclusion of codes in this policy is for reference only and does not guarantee coverage; follow the member's benefit plan and federal/state/contractual requirements.

Required clinical documentation: duration of CLBP (typically ≥ 6 months), documentation of failure of conservative therapies (e.g., physical therapy, pharmacologic management, injections), MRI evidence of Modic type 1 or 2 changes at L3–S1, and results of diagnostic procedures when applicable.
Diagnostic/prior steps expected: conservative management trial(s), appropriate imaging (MRI), and use of diagnostic/prognostic procedures as recommended by guidelines (e.g., medial branch or other targeted diagnostic blocks when clinically indicated prior to RFA).
Coding note (reference only): CPT 64628/64629 describe thermal destruction of intraosseous basivertebral nerve; CPT 64999 noted for unlisted nervous system procedures in other RFA contexts. Listing of codes does not imply coverage.

Denial Risk

Denial Risk for Unproven Ablative Techniques

Some ablative techniques are identified as unproven or not medically necessary because of insufficient or low-quality evidence. Requests for these procedures carry a higher risk of denial unless robust, plan-allowed justification and supporting clinical evidence are provided.

Examples of techniques with denial risk: pulsed RFA of facet nerves or dorsal root ganglion, endoscopic RFA/rhizotomy, cryoablation/cryodenervation, cooled RFA, chemical ablation, and laser ablation.
Ablation for sacroiliac pain and certain intraosseous procedures may also be considered unproven depending on the clinical indication and evidence quality presented.

Denial Risk

Insufficient High-Quality Evidence May Trigger Denial

Insufficient high-quality evidence (e.g., lack of well-designed RCTs, small sample sizes, short follow-up, or inconsistent results) may be a basis for medical necessity denial for BVN RFA or related ablative procedures. When evidence is limited or conflicting, approvals are less likely without strong, individualized rationale and complete documentation.

Evidence concerns cited include open-label designs, industry sponsorship, sham-control crossover or high crossover rates, and lack of long-term comparative data.
When clinical trial results are inconsistent (e.g., benefits observed but not superior to sham), expect careful review and potential denial.

Note

Plan and Contract Requirements Govern Coverage

Coverage determinations are governed by the member's benefit plan and any applicable federal, state, or contractual requirements. This policy provides guidance but does not override plan terms. In the event of conflict, the benefit plan or legal requirements take precedence.

Before submitting authorization requests, verify the member's specific plan benefits, medical necessity criteria, and any state or federal mandates that may apply.
UnitedHealthcare may modify policies and uses third-party tools (e.g., InterQual) to assist in benefit administration.

Documentation Required

Documentation and Decision Support

Provide complete clinical documentation to support authorization decisions. UnitedHealthcare may use third-party decision support tools in adjudication. Incomplete records or missing diagnostic/test results can delay review or lead to denial.

Include operative notes, imaging reports (MRI with description of Modic changes when relevant), prior treatment records (physical therapy, medications, injections), and results of diagnostic/prognostic blocks when used.
If prior authorization criteria require specific findings (e.g., Modic type 1 or 2 between L3–S1 for BVN RFA), explicitly reference and attach the supporting imaging and clinical notes.

Step Therapy

Recommended Prior and Diagnostic Steps

Clinical guidelines and expert recommendations support a sequence of conservative and diagnostic steps prior to consideration of RFA procedures. Authorization is more likely when evidence of adherence to these recommended prior steps is provided.

Recommended prior/diagnostic steps: adequate trial of conservative therapies (e.g., physical therapy, medications, activity modification), appropriate imaging (MRI), and positive response to diagnostic or prognostic blocks (e.g., medial branch blocks for facet-mediated pain) when indicated by guidelines.
Step therapy implication: failure of conservative and less invasive therapies may be required before BVN RFA approval; document duration and specifics of prior therapies and objective measures of inadequate response.

Conservative Care and Diagnostic Requirements

Policy references diagnostic/prognostic blocks and conservative care in evidence but does not state explicit mandated conservative treatment durations or steps in provided text

Policy cites diagnostic/prognostic blocks and conservative care in the supporting evidence but does not mandate specific conservative treatment durations or stepwise requirements in the provided text:

Evidence references but no explicit mandated steps: The policy references the use of diagnostic SIJ injections, prognostic lateral branch blocks, and conservative management approaches in trial designs, but does not specify explicit mandated conservative treatment durations or a stepwise sequence in the policy excerpt provided.

Referenced in randomized CRFA vs standard medical management trial and supporting evidence

Documentation of prior conservative therapy attempts is expected — ≥ 6 months symptoms and prior conservative care

Documentation expectations for conservative therapy prior to consideration of intraosseous BVN RFA:

Documentation of prior conservative therapy: Patient has chronic low back pain (CLBP) of at least 6 months' duration and documentation demonstrates prior conservative therapies were attempted (e.g., pharmacologic management, physical therapy, injections), with baseline ODI and pain scores recorded.>= 6 months of symptoms

Derived from inclusion criteria used in BVN randomized trials and manufacturer-sponsored protocols

Failure of nonsurgical treatment — referenced as requirement (leaf criteria unspecified in excerpt)

Requirement referenced in guideline recommendations for radiofrequency denervation referrals:

Failure of nonsurgical treatment: Nonsurgical treatments should have failed and the main source of pain should be identified before referral for radiofrequency denervation.

NICE recommends referral for radiofrequency denervation only when nonsurgical treatment has not worked

Positive diagnostic medial branch block — referenced as diagnostic prerequisite before facet RFA (details not expanded in excerpt)

Diagnostic prerequisite referenced for lumbar facet RFA in guidelines:

Positive diagnostic medial branch block: A positive diagnostic medial branch block is recommended as the prognostic screening test before lumbar facet radiofrequency ablation.

ASRA consensus guidelines and NICE recommend medial branch block prior to RFA

Imaging Requirements for Procedural Candidate Selection

Documentation Required

Imaging implied for some procedures — expect image guidance for BVN, CRFA, cryorhizotomy

Imaging is implied or expected for certain procedures referenced in the policy (for example intraosseous BVN RFA, CRFA, and CT‑guided cryorhizotomy) and CPT descriptors for some codes include 'with image guidance'.

Some procedures in studies used CT or fluoroscopic image guidance
CPT descriptors and code usage imply image guidance for certain procedures (e.g., intraosseous BVN RFA)

Documentation Required

BVN RFA — MRI showing Modic type 1 or 2 required/expected for consideration

Consideration for BVN RFA requires MRI demonstrating Modic type 1 or 2 changes at the treated vertebral levels (L3–S1) as used in the randomized trials and inclusion criteria.

Modic type 1 or 2 vertebral endplate changes on MRI between L3 and S1 were required in BVN RCTs
Document MRI findings in authorization and operative notes

Note

Imaging requirement — facet joint RFA does not require imaging per policy guidance

For lumbar facet joint radiofrequency denervation, NICE guidance states imaging is not required as a prerequisite; diagnostic medial branch block and clinical criteria drive selection.

NICE: Do not offer imaging as a prerequisite for radiofrequency denervation for facet joint pain
Selection should be based on clinical assessment and positive diagnostic medial branch block

Frequency Limits and Repeat Procedure Guidance

Frequency limits — general note

Policy excerpt on frequency limitsNo explicit frequency limits provided in the policy excerpt for many ablative procedures

Coding table noteListing of CPT and unlisted procedure codes does not imply coverage or frequency rules

Provider verification recommendedProviders should follow applicable federal, state, and contractual requirements for authorization and frequency

Medial branch neurotomy / facet joint nerve ablation — frequency

Suggested repeat intervalNo more frequently than every 6 months per region if ≥50% relief is obtained for 5–6 months

Maximum per yearMaximum of two procedures per region per year (ASIPP guidance)

Multi-region guidanceIf multiple regions are treated, therapeutic frequency should remain at intervals of at least 6 months per region

Medial branch neurotomy / facet RFA — frequency

Typical annual limitTypically no more than two RFA procedures per year for recurrence of pain

Interval recommendationIntervals of at least 6 months per region are suggested before repeating medial branch neurotomy/facet RFA

Outcome-based repeatRepeat procedures recommended for patients who had a good initial outcome, often defined as ≥50% pain relief at 3 months (ASRA)

Definitions of Ablative Techniques

Cooled Radiofrequency Ablation

DefinitionCooled Radiofrequency Ablation: application of continuous high-frequency electrical current to ablate nerve tissue using water-cooled electrodes/probes.

PurposeUsed to create larger lesion zones for denervation (e.g., facet or sacroiliac joint targets)

Contrast to conventional RFAUses water-cooled probes to potentially increase lesion size compared with traditional thermal RFA

Pulsed Radiofrequency Ablation

DefinitionPulsed Radiofrequency Ablation: delivers intermittent short bursts of energy (rather than continuous energy) using a probe temperature of 42 to 45° C.

MechanismNon-continuous energy delivery intended to modulate neural function while minimizing thermal destruction

Coding noteCPT code 64999 is noted in the policy for pulsed radiofrequency ablation

Basivertebral nerve ablation (BVNA)

DefinitionBasivertebral nerve ablation (BVNA): percutaneous intraosseous radiofrequency ablation targeting the basivertebral nerve to treat vertebrogenic chronic low back pain, typically in patients with Modic type 1 or 2 changes at L3–S1.

Clinical trial evidenceRandomized sham-controlled SMART trial and pooled analyses report clinically meaningful ODI and pain improvements in appropriately selected patients

Documentation expectationPrior conservative therapies and MRI evidence of Modic type 1 or 2 changes are cited as trial inclusion criteria and expected documentation elements

Cooled radiofrequency ablation (CRFA)

DefinitionCooled radiofrequency ablation (CRFA): a variant of radiofrequency ablation that uses cooled probes to create larger lesion zones for denervation of facet or sacroiliac joint–related pain.

Evidence summaryMeta-analysis and cohort studies report pain reductions after CRFA but emphasize need for high-quality RCTs to validate findings

Typical indicationsUsed for facet-mediated or sacroiliac joint pain refractory to conservative therapy in studied cohorts

Intraosseous RFA of the basivertebral nerve (Intracept)

Synonym / device nameIntracept (proprietary basivertebral nerve ablation procedure) — percutaneous intraosseous RFA of the basivertebral nerve.

Procedure descriptorThermal destruction of intraosseous basivertebral nerve, typically with image guidance; CPT descriptors include 64628/64629 for first and additional vertebral bodies.

Trial evidenceSMART randomized, sham-controlled trial (Fischgrund et al.) included participants with Modic type 1 or 2 changes and reported clinically meaningful ODI improvements at 3 months and sustained benefits in extensions

Medial branch diagnostic block

DefinitionMedial branch diagnostic block: an image-guided anesthetic injection of the medial branch nerve(s) used as a prognostic screening test before lumbar facet RFA.

Guideline roleNICE and ASRA recommend a positive diagnostic medial branch block prior to performing radiofrequency denervation for facet joint pain.

Outcome criterion linkagePositive blocks are used to identify patients likely to achieve significant pain relief (guidelines often define a good outcome as ≥50% relief at follow-up).

OpenPayer

Ablative Treatment for Spinal Pain (for New Jersey Only)

Coverage Criteria — Ablative Procedures for Spinal Pain

Applicable Procedure and Billing Codes

Provider Actions, Prior Authorization, and Documentation

Conservative Care and Diagnostic Requirements

Imaging Requirements for Procedural Candidate Selection

Frequency Limits and Repeat Procedure Guidance

Definitions of Ablative Techniques

Background — Ablative Techniques Overview

Not Covered / Excluded Procedures

Policy Revision History